The company posted second quarter revenues of $494.7 million, up from $481.8 million in Q2 2014 and beating the average Wall Street estimate of $481.7 million.
The scientists from UC Berkeley and UCSF said their method of introducing gene editing could lead to experiments in T cell function as well as immunotherapies.
The company is developing a search application that will allow users to explore genomic datasets without accessing sensitive information.
The five-year grant will support optimizing the use of polymyxin B to treat Gram-negative bacterial infections and identify protein biomarkers of drug-associated toxicity.
The researchers will use the expressed proteins to refine and optimize multiple-reaction monitoring assays that they will then apply to actual biological samples.
The New York Times' George Johnson muses on cancer's roots in multicellularity.
The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.
Jun Wang, the chief executive of BGI, has stepped down.
In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.